Credit: R Photography Background/Shutterstock. Merck & Co has received European Commission (EC) approval for the use of Keytruda (pembrolizumab ... recommendation from the Committee for Medicinal ...

This post was written by Luke Carberry Mogan. The company, which has faced slumping sales in its signature product, released the iPhone 16, with an upgraded Siri, AI text editing and photo-recognition ...

These companies focused as much on cod liver oil, toothpaste, citric acid for soft drinks, and hair gel as on prescription medicines, as well as selling products like heroin on the over-the ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

At the European Society for Medical Oncology Congress on September 13–17, promising results from the Phase III KEYNOTE-522 study involving MSD's neoadjuvant Keytruda (pembrolizumab) plus ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Patients with early triple-negative breast cancer had improved survival outcomes after receiving presurgical Keytruda plus chemotherapy and postsurgical Keytruda. Patients with early-stage ...

Merck (NYSE:MRK) announced Saturday that its ant-PD-1 therapy Keytruda (pembrolizumab) reached the main goal in a Phase 3 trial with chemoradiotherapy in patients with cervical cancer, cutting ...